US2010292451A1PendingUtilityA1

Method for diagnosing selected adenocarcinomas

Assignee: UNIV SOUTH FLORIDAPriority: Aug 27, 1996Filed: Nov 16, 2009Published: Nov 18, 2010
Est. expiryAug 27, 2016(expired)· nominal 20-yr term from priority
G01N 33/57557G01N 33/57545G01N 33/57535G01N 33/5755C12Q 2600/158G01N 2333/495C12Q 1/6886
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for the early diagnosing of selected adenocarcinomas in a human comprising the steps of removing a bodily sample from the human, and assaying the bodily sample for elevated expression of a specific gene. The gene being assayed for in the bodily sample is the TGFB-4 gene (hereinafter referred to as the endometrial bleeding associated factor (ebaf) gene. The bodily sample can be tissue from a specific organ in the body, or a blood sample. Increased levels of ebaf in the sample relative to basal levels may be indicative of a mucinous adenocarcinoma of the colon or ovaries, or an adenocarcinoma of the testis.

Claims

exact text as granted — not AI-modified
1 . An isolated polynucleotide that hybridizes to the ebaf gene. 
     
     
         2 . An isolated polynucleotide, wherein the isolated polynucleotide hybridizes to the polynucleotide of SEQ ID NO: 1.

Join the waitlist — get patent alerts

Track US2010292451A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.